- Home
- CMMB vs RDHL Comparison
CMMB vs RDHL Comparison
Compare CMMB & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- RDHL
- Stock Information
- Founded
- CMMB 2004
- RDHL 2009
- Country
- CMMB Israel
- RDHL Israel
- Employees
- CMMB N/A
- RDHL N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- CMMB Health Care
- RDHL Health Care
- Exchange
- CMMB Nasdaq
- RDHL Nasdaq
- Market Cap
- CMMB 22.0M
- RDHL 3.9M
- IPO Year
- CMMB N/A
- RDHL N/A
- Fundamental
- Price
- CMMB $2.63
- RDHL $1.66
- Analyst Decision
- CMMB Strong Buy
- RDHL
- Analyst Count
- CMMB 2
- RDHL 0
- Target Price
- CMMB $26.50
- RDHL N/A
- AVG Volume (30 Days)
- CMMB 149.9K
- RDHL 43.1K
- Earning Date
- CMMB 11-13-2025
- RDHL 09-05-2025
- Dividend Yield
- CMMB N/A
- RDHL N/A
- EPS Growth
- CMMB N/A
- RDHL N/A
- EPS
- CMMB N/A
- RDHL N/A
- Revenue
- CMMB N/A
- RDHL $9,550,000.00
- Revenue This Year
- CMMB N/A
- RDHL $381.91
- Revenue Next Year
- CMMB N/A
- RDHL N/A
- P/E Ratio
- CMMB N/A
- RDHL N/A
- Revenue Growth
- CMMB N/A
- RDHL 157.62
- 52 Week Low
- CMMB $2.61
- RDHL $1.06
- 52 Week High
- CMMB $9.84
- RDHL $11.70
- Technical
- Relative Strength Index (RSI)
- CMMB 18.39
- RDHL 60.30
- Support Level
- CMMB $2.59
- RDHL $1.47
- Resistance Level
- CMMB $3.09
- RDHL $1.71
- Average True Range (ATR)
- CMMB 0.17
- RDHL 0.09
- MACD
- CMMB -0.02
- RDHL 0.04
- Stochastic Oscillator
- CMMB 4.65
- RDHL 88.84
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.